MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Annexon Accounts Payables 2011-2026 | ANNX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Annexon
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.9 M | 10.4 M | 5.49 M | 7.42 M | 11.2 M | 3.73 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.9 M | 3.73 M | 8.86 M |
Quarterly Accounts Payables Annexon
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.2 M | 11.5 M | 6.75 M | 4.13 M | 3.97 M | 4.81 M | 7.16 M | 10.3 M | 7.42 M | 6.92 M | 10.3 M | 9.38 M | 11.2 M | 4.8 M | 4.18 M | 4.52 M | 3.73 M | 3.73 M | 3.73 M | 3.73 M | 2.37 M | 2.37 M | 2.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.2 M | 2.37 M | 6.42 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 21.77 | 1.68 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Aptorum Group Limited
APM
|
3.24 M | $ 0.92 | 3.05 % | $ 6.76 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
16.2 M | $ 22.44 | 2.16 % | $ 3.72 B | USA |
 |
Esperion Therapeutics
ESPR
|
65.1 M | $ 2.02 | 5.76 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
3.24 M | $ 2.42 | 3.65 % | $ 155 M | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Heron Therapeutics
HRTX
|
8.99 M | $ 1.26 | 6.3 % | $ 210 M | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
792 K | $ 8.28 | -0.84 % | $ 74.7 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
7.07 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
78 K | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
29.9 M | $ 4.14 | 1.47 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 23.57 | 1.33 % | $ 3 B | USA |
 |
Jaguar Health
JAGX
|
8.69 M | $ 0.36 | -8.39 % | $ 840 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.46 | 1.04 % | $ 389 M |  Britain |
 |
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
KalVista Pharmaceuticals
KALV
|
8.27 M | $ 20.08 | 2.29 % | $ 1.08 B | Britain |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 2.99 | 2.05 % | $ 4.92 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |